Uterine Neoplasms, Version 3.2025 Featured Updates to the NCCN Guidelines®

Nadeem R. Abu-Rustum, Susana M. Campos, Sudha Amarnath, Rebecca Arend, Emma Barber, Kristin Bradley, Rebecca Brooks, Junzo Chino, Hye Sook Chon, Marta Ann Crispens, Shari Damast, Christine M. Fisher, Peter Frederick, David K. Gaffney, Stephanie Gaillard, Robert Giuntoli, Scott Glaser, Brooke E. Howitt, Lisa Landrum, Jayanthi LeaNita Lee, Gina Mantia-Smaldone, Andrea Mariani, David Mutch, Christa Nagel, Larissa Nekhlyudov, Karina Nieto, Chika Nwachukwu, Mirna Podoll, Kerry Rodabaugh, Ritu Salani, John Schorge, Scott Schuetze, Jean Siedel, Rachel Sisodia, Pamela Soliman, Stefanie Ueda, Renata Urban, Emily Wyse, Nicole McMillian, Vaishnavi Sambandam

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

The NCCN Guidelines for Uterine Neoplasms provide recommendations for diagnostic workup, clinical staging, and treatment options for patients with endometrial cancer and uterine sarcoma. The NCCN Cervical Uterine Panel meets at least annually to review comments from reviewers within their institutions; examine relevant new data from publications, abstracts, and recent FDA approvals; and reevaluate and update recommendations. These NCCN Guidelines Insights summarize the panel’s deliberations on the new FIGO 2023 staging system and updates on the new systemic therapy recommendations for the management of endometrial cancer.

Original languageEnglish
Pages (from-to)284-291
Number of pages8
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume23
Issue number8
DOIs
StatePublished - Aug 2025

Fingerprint

Dive into the research topics of 'Uterine Neoplasms, Version 3.2025 Featured Updates to the NCCN Guidelines®'. Together they form a unique fingerprint.

Cite this